This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

VaxGen Stockholder Vote Insufficient To Approve Merger With OXiGENE

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN) announced preliminary results of the vote from its special stockholder meeting held on February 3, 2010.

(Logo:  http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

VaxGen stockholders voted on two proposals. The first proposal, to approve and adopt the Agreement and Plan of Merger among OXiGENE, VaxGen, a wholly-owned subsidiary of OXiGENE, and James P. Panek as the VaxGen stockholder representative, was not approved. 13,229,539 shares voted FOR the merger, 9,492,159 shares voted AGAINST and 26,176 ABSTAINED. The approval of a majority of the Company's total outstanding shares was required to approve the merger. Therefore, a FOR vote totaling 16,553,263 shares was required to approve the merger.

The second proposal, to adjourn the special meeting if necessary, to solicit additional proxies if there were not sufficient votes in favor of the merger, was approved, with approximately 57.7% of the shares voted FOR and 42.3% AGAINST. This proposal needed only a majority of the votes cast to be approved. However, under the terms of the merger agreement, VaxGen was not permitted to adjourn or postpone the meeting without the prior consent of OXiGENE. Prior to the meeting, and based on this anticipated vote result, VaxGen requested OXiGENE's consent to adjourn the meeting to allow additional time to solicit proxies. The OXiGENE board of directors declined to provide OXiGENE's consent to the requested adjournment.

"We are obviously very disappointed that the proposed merger with OXiGENE did not receive the votes necessary for approval," said James P. Panek, VaxGen President. "We achieved substantial support for the merger from our stockholders, with approximately 58% of the shares voted in favor of the merger, representing 40% of the Company's total outstanding shares. However, more than 31% of the outstanding shares were not voted. We believe that with additional time, there was a reasonable likelihood that we could have achieved the necessary vote. We are disappointed that the OXiGENE board was unwilling to consent to an adjournment of our meeting to solicit these un-voted shares."

The VaxGen Board of Directors intends to immediately assess the Company's strategic alternatives.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,104.00 -9.54 -0.06%
S&P 500 1,988.64 +5.11 0.26%
NASDAQ 4,478.64 +22.6240 0.51%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs